British National Formulary (2013) Diabetic neuropathy [online; accessed 15 April 2013]

Camilleri M, Parkman HP, Shafi MA et al. (2013) Clinical guideline: management of gastroparesis. The American Journal of Gastroenterology 108: 18–37

Dhir R, Richter J (2004) Erythromycin in the short and long term control of dyspepsia symptoms in patients with gastroparesis. Journal of Clinical Gastroenterology 38(3): 237–42

Erbas T, Varoglu E, Erbas B et al. (1993) Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 16: 1511–14

Fiorucci S, Distrutti E, Bassotti G et al. (1994) Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scandinavian Journal of Gastroenterology 29: 807–13

Maganti K, Onyemere K, Jones MP (2003) Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. American Journal of Gastroenterology 98: 259–63

National Institute for Health and Clinical Excellence (2004) Gastroelectrical stimulation for gastroparesis. NICE interventional procedure guidance 103

National Institute for Health and Clinical Excellence (2006) Nutrition support in adults. NICE clinical guideline 32

National Institute for Health and Clinical Excellence (2009) Type 2 diabetes – newer agents. NICE clinical guideline 87

Ramirez B, Eaker EY, Drane WE et al. (1994) Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Digestive Diseases and Sciences 39: 2295–300

Richards RD, Davenport K, McCallum RW (1993) The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. The American Journal of Gastroenterology 88: 203–7

Samsom M, Jebbink RJ, Akkermans LM et al. (1997) Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 20: 129–34